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INTRODUCTION

AAV vectors in the central nervous system
The isolation of a molecular clone of adeno-associated virus (AAV) serotype 2 into the pBR322 plasmid by Samulski in 1982 opened the door for the genetic analysis of this virus [1] [2]. The origin of replication, consisting of the two 145-nucleotide non-coding extremities (the inverted terminal repeats, or ITRs) of the viral genome was shown to be the only cis-acting element needed for replication and encapsidation of the viral DNA and for rescue from plasmids.
This discovery enabled the generation of recombinant AAV (rAAV) vectors through the cloning of heterologous genes instead of the AAV genes between the ITRs. Recombinant viral particles are then produced by providing AAV genes and some helper adenoviral genes in trans [3] [4] [5] [6].
rAAV vectors are excellent tools in gene therapy for treatment of neurological diseases as they transduce post-mitotic cells [7] [8] [9] that mediate the sustained, long-term gene expression [10] [11] that is required to treat chronic diseases. rAAV serotype 2 was the first discovered serotype and is still the best-understood but vectors deriving from several other human or simian serotypes have demonstrated both a higher efficiency and a wider distribution of transgene expression in the CNS [12] [13] [14] .
rAAV vectors have an excellent safety profile [15] . First, they elicit only low titer and transient neutralizing antibodies and no inflammation when administered in the brain [10] [16] .
Given the high seropositivity for AAV in the human population, this immune response against rAAV in the presence of circulating anti-AAV antibodies [17, 18] , is a particularly important issue [19] . It has been demonstrated recently that after intraparenchymal injections into the CNS, transgene expression is unaffected in immune-primed mice harbouring physiologically-relevant anti-AAV2 antibodies levels [20] . Notably, there are significant differences in the immune responses toward the different AAV serotypes in the human population. In particular, healthy mutations in the CLN2 gene encoding a lysosomal tripeptidyl-peptidase whose deficiency causes accumulation of proteins in lysosomes of neurons leading to neuronal cell death. A rAAV2 vector expressing the human CLN2 cDNA was administered to 12 locations in the CNS of 10 children, enrolled in a Phase I clinical trial for Batten disease. Although this trial was not double-blinded and randomized, the data suggested, on the basis of a neurologic rating scale, that the rate of decline was significantly reduced in treated patients [46] . On the basis of promising preclinical studies [47] , another clinical trial using the more efficient AAVrh10 serotype has been launched (http://www.abedia.com/wiley/record_detail.php?ID=1717).
Mucopolysaccharidosis type III (MPSIII), a disorder caused by the absence of one of the lysosomal enzymes required for the degradation of heparan sulfate (HS) which results in the accumulation of heparan sulfate oligosaccharides (HSOs) is also an interesting target for rAAVmediated gene therapy. In MPSIIIB, -N-acetylglucosaminidase (NaGlu) deficiency in particular is responsible for progressive mental neurodegeneration. Intracerebral stereotactic injections of AAV5 vectors coding for the missing enzyme reversed alterations of HS degradation, corrected pathology in neuronal cells and prevented neuroinflammation at the organ level in animal models [48] . Recently, a clinical trial using a rAAVrh10 vector has been launched for MPSIIIA, a deficiency in heparan-N-sulfamidase (http://www.abedia.com/wiley/record_detail.php?ID=318).
Parkinson's disease (PD) is also a good candidate for gene therapy since the main symptoms are caused by the progressive degeneration of a specific neuron population, the nigro-striatal dopaminergic (DA) neurons, located in a precise brain area, leading to the cardinal motor symptoms: bradykinesia, rigidity and tremor. Thanks to the discovery of the important role of dopamine depletion in PD, a breakthrough in the pharmacological treatment of PD was made in the 1960s, in the form of the oral administration of L-dopa, the precursor to dopamine [49] . Exogenous L-dopa is taken up into the remaining functional DA neurons where it is converted into dopamine by aromatic acid decarboxylase (AADC). With the ongoing loss of DA neurons, though, the uptake of extracellular L-dopa declines and increasing doses of L-dopa need to be administered leading to important fluctuations (e.g. peak-dose dyskinesias). Continuous delivery of L-dopa directly to the striatum via gene therapy could be a significant improvement because L-dopa would reach only the clinically relevant target area [50] . A rAAV2 vector expressing AADC has been injected in PD patients' putamen in an attempt to reduce and stabilize the L-dopa dose necessary to alleviate the symptoms [51] . This combined treatment is predicted to provide more stable dopamine levels in the long-term than oral L-dopa treatment alone since AAV2-hAADC therapy results in expression of AADC in non-degenerating putaminal neurons [52] , in contrast to nigral neurons that express endogenous AADC. Ten patients received bilateral intraputaminal infusions of 2 different doses of rAAV2-AADC (9 x 10 10 and 3 x 10 11 vg). Data based on PET imaging using a AADC-specific tracer [51] fluoro-L-tyrosine) [53] demonstrated stable transgene expression over 4 years confirming the preclinical data on the longevity of rAAV-mediated transgene expression [11] . This clinical trial further confirmed the safety and tolerability of rAAV intracerebral administration [54] but emphasized the need for a higher vector dose. The data showed dose-dependent improvements but even in the high-dose group in which the Unified Parkinson's disease Rating Scale (UPDRS) improved in all patients in the first 12 months, a slow deterioration was observed in subsequent years [53] .
The motor abnormalities in PD are due to the overactivity of major output nuclei of the motor loop caused by the lack of dopamine in the striatum. Controlled inhibition of these excessively active nuclei can restore a normalized output to the cortex. Consistently, inhibiting the activity of the subthalamic nucleus (STN) by implanting adjustable electrodes provided impressive and immediate reversal of symptoms [55] . Using a similar paradigm, a rAAV2 vector expressing glutamic acid decarboxylase, the enzyme that synthesizes the inhibitory neurotransmitter GABA was injected in the STN. In preclinical studies, the vector transduced excitatory glutamatergic neurons which became inhibitory thereby reducing the STN activity [56] . A Phase I clinical trial demonstrated safety and tolerability of rAAV2 injections into the STN. Furthermore, 10 of 12 patients showed improvements in UPDRS at 12 months [57] . A subsequent double-blinded shamsurgery controled trial involving 16 patients injected with AAV2-GAD and 21 receiving control sham-surgery, confirmed the UPDRS improvements [58] . In this study, in which 23 controls and 22 treated patients were originally enrolled, in order to reinforce the statistical relevance of the data, the authors excluded from the analysis, the individuals for which identified technical failures occurred during the surgery.
However effective, these therapeutic strategies might be, though, they are only compensatory and are not expected to interfere with DA neuron cell death.
Providing neurotrophic support might constitute the first disease-interfering approach for PD. Glial cell line-derived neurotrophic factor (GDNF) and its analog Neurturin (NTN) were shown to protect and even in some instances restore DA neurons in most animal models (with the exception of alpha-synuclein overexpression [59] . The fact that GDNF can be retrogradely transported from the striatum to the substantia nigra pars compacta [65] provides an interpretation for this observation.
A rAAV2 vector expressing NTN is currently being evaluated in Phase II clinical trials [66] .
In a first trial, the virus was injected in the putamen (5. clinical trial using minipumps to deliver recombinant GDNF protein in patients' brain was interrupted due to the appearance of antibodies directed against GDNF [73] . Although none of these adverse effects have beed described so far in the AAV2-NTN gene therapy clinical trials, these observations raised the issue of the pharmacological aspects of rAAV-mediated gene delivery.
A variety of vectors are being designed and continuously improved to adapt to the needs of these very diverse situations. In some cases, localized (e.g GDNF) and cell-type specific (e.g. GAD) expression is required whereas in cases like MPSIII, brain-wide and efficient transgene expression is a prerequisite to success. In some cases, such with as the correction of enzymatic deficiencies, maximizing transgene expression is the ultimate goal whereas in other cases, such with many neuroprotective strategies, it will be necessary to regulate transgene expression in order to adapt the dose of the transgene product to the patient's needs and eventually terminate the treatment. The on-going development of better targeted and better regulated rAAV vectors is described in the following sections. activation domain to reduce its toxicity due to sequestering of transcriptional cellular factors [87] .
REGULATION OF TRANSGENE EXPRESSION
A reverse transactivator (rtTA) which, unlike the Tet-Off system, responds to the presence mg/ kg) in the striatum. The corresponding Dox serum levels were at least 8-fold lower than levels required for antimicrobial activity [106] and similar to those currently used as anti-inflammatory drug to treat rosacea [107] , suggesting that clinically-acceptable Dox doses could be useful to regulate GDNF transgene expression in clinical trials.
Single rAAV using the Tet-On system were also described [101] [108] [80] . Using the rtTA2(S)M2 mutant developed by Urlinger, the quantity of Dox given to rats to achieve a biological effect was 600µg/ml in drinking water, equivalent to 70mg/kg for the GDNF transgene [108] [80]
( Fig.2) and 3mg/kg for miRNA expression [101] .
The constant antibiotics administration could lead to complications such as increased tolerance to tetracyclines or toxicity. Therefore, in order to minimize the period of treatment, the choice of an adequate version of the Tet-based system, will rely on the disease to be treated and the therapeutic strategy.
Due to the blood-brain barrier (BBB), the effective inducer dose required for the biological effect of a transgene delivered into the brain is less feasible than for one delivered to the peripheral organs. To overcome this difficulty, attempts have been made to optimize the genetic components improve bioavailability in the brain thanks to more efficient passage through the BBB. Besides Dox, other tetracyclines are able to induce the tTA and rtTA. Methacycline [112] , has an induction potency similar to Dox with a shorter half-life [113] which is an advantage for faster clearance.
Minocycline is also a good inducer for the tTA and some versions of the rtTA [112] [114] and furthermore has the advantage to be anti-inflammatory in the brain [115] [116]. 4-epidoxycycline, a Dox metabolite without antibiotic activity which can induce the Tet-system [117] could also be an alternative. Chemically-modified tetracyclines (CMT) devoid of antibiotic activity [101] are also interesting but are not Tet-system inducers. Other inducers showing a higher affinity for rtTA2(S)M2 [91] than Dox on the basis of structural analysis while keeping the ability of Dox to cross the BBB have been discovered [118] . Finally, an alternative strategy to rapidly stop transgene [126] . Indeed, tTA [127] and rtTA2(S)M2 do not elicit striatal immune response even when rats are pre-immunized [124] . However, the rodent immune system does not correlate directly with that of humans and the vast majority of the human population (60%) has been exposed to herpes simplex virus [128] . They may thus have circulating antibodies against the VP16 portion of the tTA/rtTA, which could block transgene expression. The use of immunologically-humanized mice could help predict the immune response to the Tet transactivator in patients [129] . Attemps to replace the viral VP16-derived activator domain by the human p65 activation domain of the NFκB complex, could help reducing the immunogenicity of the Tet transactivator [130] . In this respect, the use of autoregulatory vectors avoiding permanent expression of Tet-transactivators constitutes an improvement [102] [103] [131] . Epitope analysis and subsequent predictive design of new less immunogenic transactivators could help minimizing the deleterious effect of pre-existing HSV-1 seropositivity.
Another drug-inducible framework proposed for regulation AAV-mediated transgene expression in the brain is the rapamycin-inducible system [132] . However, until now this dualvector system provides transgene expression levels that are much lower than constitutive promoters [78] .
Methods to regulate transgene products posttranscriptionally have also been proposed.
Although still in their infancy, it is worth citing: the regulation of protein stability through the binding of a small ligand, trimethoprim, to a destabilizing domain [133] .
CELL TYPE-SPECIFICITY
Numerous AAV capsid variants, either naturally occuring (serotypes) or laboratoryengineered (by random mutagenesis or rationally-designed modifications), have been described [79] [ [152] . The majority of the tested serotypes or variants tested in rodents, mediate transgene expression mainly in neurons with the exception of AAVrh43 and rAAV4 which transduce glial cells [153] and ependymal cells [148] respectively, when injected in the striatum. In contrast, in monkeys a high proportion of reporter gene positive glial cells were observed with rAAV5 [151] and rAAV1 [154] .
In addition, different AAV serotypes transduce different neuronal subtypes. For example, in the rat hippocampus, rAAV2 targets dendate gyrus neurons whereas rAAV1 and 5 are more efficient in pyramidal neurons [12] . In the rat SN, rAAV2 mediates transgene expression exclusively in SN pars compacta [155] while rAAV1 and rAAV5 transduce pars compacta and pars reticulata with similar efficiency [12] . Interestingly, the bb2 serotype transduces only medium spiny neurons in the rat striatum [153] .
Other factors affecting rAAV cellular specificity include : the promoter, the age of the animals and the purity of the viral preparation. For example, rAAV8 using constitutive promoters almost exclusively mediate neuronal expression in adult brain. However, contaminants present in the stocks affected the virus' tropism resulting in a low propostion of astrocytes [34] . The mode of delivery can also determine the cell-type specificity of rAAV-mediated transgene expression. When injected in the brain parenchyma, rAAV9 directs transgene expression mainly in neurons [34] [35].
In contrast, intravascular rAAV9 delivery results in a variable percentage of astrocytes expressing the transgene depending on the age of the animal, the species and the structure of the rAAV genome. Indeed, when injected in the facial vein of new born and adult C57Bl/6 mice, respectively, mainly neurons or astrocytes expressed the transgene [31] . In addition, Gray et al. [41] reported that self-complementary AAV9 (a double-stranded form of AAV genome generated using a mutant ITR; see below) injected in the tail vein of adult BALB/c mice transduced twice as many neurons as astrocytes. This discrepancy might be explained by the injection site, the mice species or the genomic structure. Gray et al. further demonstrated that traditional single-stranded rAAV were far less efficient than self-complementary vectors. Finally, when the same vector was injected in the saphenous vein of non-human primate they observed a mainly astrocytic transduction [41] .
Neuronal transduction was also reported by Duque and coll. in the spinal cord of adult mice after intravenous injection of self-complementary AAV9 in the temporal vein [32] .
Differential rAAV cell-type specificity between fetal and adult brain was also reported. In rat fetal midbrain striatal grafts, rAAV1 allowed massive transduction of DA neurons whereas rAAV2 exclusively transduced non-DA neurons (Fig. 2) contrasting with rAAV2 tropism for adult midbrain DA neurons [155] . Similarly, rAAV1 but not rAAV5 encapsidating the same viral genome transduced fetal striatal neurons, whereas both very efficiently transduced adult striatum [156] . Interestingly, enhanced glial gene delivery in the brain has been obtained by selecting AAV capsid variants through molecular evolution [5] .
In order to restrict transgene expression in target cell populations, different cell type-specific promoters were tested. For example, using rAAV2, the neuron-specific enolase promoter mediated restricted expression into neurons [10] whereas with the cytomegalovirus (pCMV) promoter, a small proportion of astrocytes also expressed the reporter gene. Similar results were obtained with the human synapsin I promoter (phSYN) [157] . As expected, the tyrosine hydroxylase promoter allowed transgene expression restricted to DA neurons [158] . An elegant study using rAAV5-encapsidated bicistronic vectors comprising one expression cassette using a promoter sequence derived from the murine CMV (pmCMV) and another under the control of phSYN showed that pmCMV drives expression in cells located in the striosomes (possibly oligodendrocytes) whereas phSYN-driven expression was strictly neuronal [159] . In an experiment using rAAV8 and rAAVrh43 in combination with the GFAP astrocytic promoter, or the myelin basic protein (MBP)
promoter active in oligodendrocytes Lawlor observed an expression restricted to astrocytes with GFAP promoter with both serotypes. With MBP promoter, in contrast, they observed reporter gene expression mostly in oligodendrocytes with rAAV8 and in both astrocytes and oligodendrocytes with rAAVrh43. Surprisingly, when rAAVrh43 pMBP was injected into the hippocampus, a weak expression of the reporter gene was only observed in a subpopulation of dentate gyrus neurons [153] indicating the necessity to take into account cell-specific promoters and capsid variants for targeting.
Viral or composite promoters thought to be ubiquituous can also affect the cell-type specificity of rAAV-mediated transgene expression. We showed that rAAV1 mediate differential specificities of transgene expression depending on whether the expression is driven by a pCMV promoter or a by Tet-ON cassette [26] . For example, in the midbrain, transgene expression was restricted to the DA regions (SNpc and VTA) with the TetON system but was widespread in the midbrain with pCMV. Promoter-related differential transduction has also been demonstrated in a functional assay. In an epilepsy model, rAAV2 vectors expressing a NMDA receptor-1 (NR1)
antisense under the control of pCMV and Tet-Off promoters caused an increase in seizures while pCMV-driven NR1 antisense expression lead to a significant reduction in seizures. Co-infusing these two vectors, each expressing a different reporter gene, demonstrated that they specify gene expression into different neuronal populations [131] .
Intravascularly-administered rAAV6, rAAV8 and rAAV9 [58] are able to deliver genes to the brain. However, using this delivery mode, transgene expression is dramatically more efficient in the liver, spleen and heart than in the brain [41] . In order to restrict transgene expression to the CNS, Gao successfully repressed rAAV9 expression outside the CNS using a tissue-specific miRNA [160] .
Another limiting step in rAAV-mediated gene delivery is the conversion of the singlestranded viral DNA into a transcriptionally-active double-strand DNA. The synthesis of the second strand complementary to the viral DNA is mediated by cellular factors which are present in limiting concentrations depending on the cell type [79] ). Based on the discovery that (+) and (-) strand forms of AAV DNA are generated during the viral vector production [156] , though, it has been proposed that when the genome copy number in a single cell is high enough, annealing of a sense sequence and an antisense sequence can occur. Based on the presence of dimeric head-to-head replicative forms, McCarty [161] has introduced a mutation within one of the ITRs which forces the encapsidation of dimers rather than monomers The two head-to-head halves of vector genomes called "self-complementary" (scAAV) can anneal and form a double-strand mediating faster and more efficient transgene expression in the brain [162] . It should be noted that, due to limited packaging capacity, the maximal genome size of scAAV is reduced by half compared to conventional vectors. ScAAV2 and scAAV1injected in the brain parenchyma mediate a faster onset of-and a stronger transgene expression than AAV2 but do not seem to alter the cellular tropism [163] [164] . Similarly, scAAV9 injected i.v. in the mice shows an efficacy similar to a 20-fold higher dose of AAV9 [41] . Rationally-based targeting can be achieved by capsid engineering [136] [5] [167] or miRNA restricted-transgene expression [168] . In the case of motoneurons diseases, targeting can also be achieved through retrograde delivery [79] [129] .
In other cases, in particular for enzymatic deficiencies, global and efficient transgene expression is a prerequisite to success. However, though global brain transduction is searched, celltype specificity might still be a limitation. In leukodystrophies, for example, the missing enzyme must be supplied to oligodendrocytes [29] . [66] , regulation of transgene expression will likely be required to avoid adverse events and, if necessary, terminate the treatment. Among the regulatable systems, the Tetsystem is the most widely used and the best-developed [42] . However, important issues remain to be solved. First, immune reactions to the VP16 portion of the Tet transactivator deriving from HSV are likely to arise in HSV-seropositive patients. Second, the inducer should be a clinically-approved molecule effective at a clinically-acceptable dose. The last developments of rAAV-based Tet-Off vectors, have shown regulation of an adverse effect of GDNF (weight loss) using a Dox dose which is below the approved anti-microbial dose [72] . However, therapeutical effects have not been addressed in this study. On the other hand, using a rAAV-tetON vector, Dox-dependent behavioral improvements have been demonstrated in a well-established rodent model of PD [80] . In this study, though, the Dox dose, by body mass was more than one order of magnitude higher than the approved dose for patients. The remaining challenges will be to characterize and eventually circumvent the immune reaction to the Tet transactivator as well as to obtain inducer-transactivator interactors fulfilling clinical requirements.
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Regulation of GDNF transgene expression mediated by a single AAV-tetON tetracycline-inducible vector in the striatum in a partial rat model of PD.
A single injection of rAAV2/1-tetON-GDNF (3.5 x 10 8 vg/rat) was performed in the rat striatum.
One month later, a 4-injection sites 6-hydroxydopamine lesion [61] was performed. Animals were continuously treated with doxycycline (A) (600 µg/l in drinking water)or remained untreated (B) and were sacrified one month post-lesioning.
Ten microns coronal sections were labeled with anti-GDNF antibodies using a peroxidase staining method [108] . The ventral mesencephali (VM) from 14-days embryos were dissected out and infected with rAAV vectors expressing eGFP reporter gene under the control of CMV promoter, trans-encapsidated into AAV1 ( rAAV1-pCMV-eGFP) or AAV2 ( rAAV2/2-pCMV-eGFP) capsids. Immediately after infection, VMs were dissociated into individual cells and animals were stereotactically infused into the right striatum with a cell suspension corresponding from the half of a VM per rat, as previously described [173] .
Four weeks posttransplantation, animals were sacrificed and 40-µm coronal brain sections were labeled using polyclonal rabbit anti-GFP antibodies (green fluorescence) and monoclonal antityrosine hydroxylase antibodies (red fluorescence). Double-labeled cells appear yellow.
Scale bar : 100µm (10X pictures) and 50 µm (40X pictures).
